Literature DB >> 24807056

Neisseria adhesin A variation and revised nomenclature scheme.

Stefania Bambini1, Matteo De Chiara1, Alessandro Muzzi1, Marirosa Mora1, Jay Lucidarme2, Carina Brehony3, Ray Borrow2, Vega Masignani1, Maurizio Comanducci1, Martin C J Maiden3, Rino Rappuoli4, Mariagrazia Pizza1, Keith A Jolley3.   

Abstract

Neisseria adhesin A (NadA), involved in the adhesion and invasion of Neisseria meningitidis into host tissues, is one of the major components of Bexsero, a novel multicomponent vaccine licensed for protection against meningococcal serogroup B in Europe, Australia, and Canada. NadA has been identified in approximately 30% of clinical isolates and in a much lower proportion of carrier isolates. Three protein variants were originally identified in invasive meningococci and named NadA-1, NadA-2, and NadA-3, whereas most carrier isolates either lacked the gene or harbored a different variant, NadA-4. Further analysis of isolates belonging to the sequence type 213 (ST-213) clonal complex identified NadA-5, which was structurally similar to NadA-4, but more distantly related to NadA-1, -2, and -3. At the time of this writing, more than 89 distinct nadA allele sequences and 43 distinct peptides have been described. Here, we present a revised nomenclature system, taking into account the complete data set, which is compatible with previous classification schemes and is expandable. The main features of this new scheme include (i) the grouping of the previously named NadA-2 and NadA-3 variants into a single NadA-2/3 variant, (ii) the grouping of the previously assigned NadA-4 and NadA-5 variants into a single NadA-4/5 variant, (iii) the introduction of an additional variant (NadA-6), and (iv) the classification of the variants into two main groups, named groups I and II. To facilitate querying of the sequences and submission of new allele sequences, the nucleotide and amino acid sequences are available at http://pubmlst.org/neisseria/NadA/.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24807056      PMCID: PMC4097447          DOI: 10.1128/CVI.00825-13

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  37 in total

1.  Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electophoretic type-37 complex.

Authors:  Leonard W Mayer; Michael W Reeves; Nasser Al-Hamdan; Claudio T Sacchi; Muhamed-Kheir Taha; Gloria W Ajello; Susanna E Schmink; Corie A Noble; Maria Lucia C Tondella; Anne M Whitney; Yagoub Al-Mazrou; Mohammed Al-Jefri; Amin Mishkhis; Sameer Sabban; Dominique A Caugant; Jairam Lingappa; Nancy E Rosenstein; Tanja Popovic
Journal:  J Infect Dis       Date:  2002-05-17       Impact factor: 5.226

2.  Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing.

Authors:  M Pizza; V Scarlato; V Masignani; M M Giuliani; B Aricò; M Comanducci; G T Jennings; L Baldi; E Bartolini; B Capecchi; C L Galeotti; E Luzzi; R Manetti; E Marchetti; M Mora; S Nuti; G Ratti; L Santini; S Savino; M Scarselli; E Storni; P Zuo; M Broeker; E Hundt; B Knapp; E Blair; T Mason; H Tettelin; D W Hood; A C Jeffries; N J Saunders; D M Granoff; J C Venter; E R Moxon; G Grandi; R Rappuoli
Journal:  Science       Date:  2000-03-10       Impact factor: 47.728

Review 3.  The virulence plasmid of Yersinia, an antihost genome.

Authors:  G R Cornelis; A Boland; A P Boyd; C Geuijen; M Iriarte; C Neyt; M P Sory; I Stainier
Journal:  Microbiol Mol Biol Rev       Date:  1998-12       Impact factor: 11.056

4.  Experimentally revised repertoire of putative contingency loci in Neisseria meningitidis strain MC58: evidence for a novel mechanism of phase variation.

Authors:  P Martin; T van de Ven; N Mouchel; A C Jeffries; D W Hood; E R Moxon
Journal:  Mol Microbiol       Date:  2003-10       Impact factor: 3.501

5.  Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease.

Authors:  David J Litt; Silvana Savino; Amanda Beddek; Maurizio Comanducci; Colin Sandiford; Julia Stevens; Michael Levin; Cathy Ison; Mariagrazia Pizza; Rino Rappuoli; J Simon Kroll
Journal:  J Infect Dis       Date:  2004-09-09       Impact factor: 5.226

6.  Molecular analysis of transport and oligomerization of the Yersinia enterocolitica adhesin YadA.

Authors:  Andreas Roggenkamp; Nikolaus Ackermann; Christoph A Jacobi; Konrad Truelzsch; Harald Hoffmann; Jürgen Heesemann
Journal:  J Bacteriol       Date:  2003-07       Impact factor: 3.490

7.  Continuing diversification of Neisseria meningitidis W135 as a primary cause of meningococcal disease after emergence of the serogroup in 2000.

Authors:  Muhamed-Kheir Taha; Dario Giorgini; Magaly Ducos-Galand; Jean-Michel Alonso
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

8.  NadA diversity and carriage in Neisseria meningitidis.

Authors:  Maurizio Comanducci; Stefania Bambini; Dominique A Caugant; Marirosa Mora; Brunella Brunelli; Barbara Capecchi; Laura Ciucchi; Rino Rappuoli; Mariagrazia Pizza
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

9.  Invasive meningococcal capsular group Y disease, England and Wales, 2007-2009.

Authors:  Shamez N Ladhani; Jay Lucidarme; Lynne S Newbold; Stephen J Gray; Anthony D Carr; Jamie Findlow; Mary E Ramsay; Edward B Kaczmarski; Raymond Borrow
Journal:  Emerg Infect Dis       Date:  2012-01       Impact factor: 6.883

10.  NadA, a novel vaccine candidate of Neisseria meningitidis.

Authors:  Maurizio Comanducci; Stefania Bambini; Brunella Brunelli; Jeannette Adu-Bobie; Beatrice Aricò; Barbara Capecchi; Marzia Monica Giuliani; Vega Masignani; Laura Santini; Silvana Savino; Dan M Granoff; Dominique A Caugant; Mariagrazia Pizza; Rino Rappuoli; Marirosa Mora
Journal:  J Exp Med       Date:  2002-06-03       Impact factor: 14.307

View more
  33 in total

1.  Structure of the meningococcal vaccine antigen NadA and epitope mapping of a bactericidal antibody.

Authors:  Enrico Malito; Marco Biancucci; Agnese Faleri; Ilaria Ferlenghi; Maria Scarselli; Giulietta Maruggi; Paola Lo Surdo; Daniele Veggi; Alessia Liguori; Laura Santini; Isabella Bertoldi; Roberto Petracca; Sara Marchi; Giacomo Romagnoli; Elena Cartocci; Irene Vercellino; Silvana Savino; Glen Spraggon; Nathalie Norais; Mariagrazia Pizza; Rino Rappuoli; Vega Masignani; Matthew James Bottomley
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-17       Impact factor: 11.205

2.  Phage display revisited: Epitope mapping of a monoclonal antibody directed against Neisseria meningitidis adhesin A using the PROFILER technology.

Authors:  Veronica Lanza Cariccio; Maria Domina; Salvatore Benfatto; Mario Venza; Isabella Venza; Agnese Faleri; Marco Bruttini; Erika Bartolini; Marzia Monica Giuliani; Laura Santini; Brunella Brunelli; Nathalie Norais; Erica Borgogni; Angelina Midiri; Roberta Galbo; Letizia Romeo; Carmelo Biondo; Vega Masignani; Giuseppe Teti; Franco Felici; Concetta Beninati
Journal:  MAbs       Date:  2016-03-10       Impact factor: 5.857

3.  Large Cluster of Neisseria meningitidis Urethritis in Columbus, Ohio, 2015.

Authors:  Jose A Bazan; Abigail Norris Turner; Robert D Kirkcaldy; Adam C Retchless; Cecilia B Kretz; Elizabeth Briere; Yih-Ling Tzeng; David S Stephens; Courtney Maierhofer; Carlos Del Rio; A Jeanine Abrams; David L Trees; Melissa Ervin; Denisse B Licon; Karen S Fields; Mysheika Williams Roberts; Amanda Dennison; Xin Wang
Journal:  Clin Infect Dis       Date:  2017-07-01       Impact factor: 9.079

4.  Susceptibility of Meningococcal Strains Responsible for Two Serogroup B Outbreaks on U.S. University Campuses to Serum Bactericidal Activity Elicited by the MenB-4C Vaccine.

Authors:  Raffaella Rossi; Peter T Beernink; Serena Giuntini; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2015-09-30

5.  Increased Risk for Meningococcal Disease Among Men Who Have Sex With Men in the United States, 2012-2015.

Authors:  Temitope A Folaranmi; Cecilia B Kretz; Hajime Kamiya; Jessica R MacNeil; Melissa J Whaley; Amy Blain; Mike Antwi; Marie Dorsinville; Massimo Pacilli; Shamika Smith; Rachel Civen; Van Ngo; Kathleen Winter; Kathleen Harriman; Xin Wang; Virginia B Bowen; Manisha Patel; Stacey Martin; Lara Misegades; Sarah A Meyer
Journal:  Clin Infect Dis       Date:  2017-09-01       Impact factor: 9.079

6.  Genetic Diversity of Meningococcal Serogroup B Vaccine Antigens among Carriage Isolates Collected from Students at Three Universities in the United States, 2015-2016.

Authors:  Henju Marjuki; How-Yi Chang; Nadav Topaz; Melissa J Whaley; Jeni Vuong; Alexander Chen; Laurel T Jenkins; Fang Hu; Susanna Schmink; Adam C Retchless; Jennifer D Thomas; Anna M Acosta; Lucy A McNamara; Heidi M Soeters; Sarah Mbaeyi; Xin Wang
Journal:  mBio       Date:  2021-05-18       Impact factor: 7.867

Review 7.  Protein Crystallography in Vaccine Research and Development.

Authors:  Enrico Malito; Andrea Carfi; Matthew J Bottomley
Journal:  Int J Mol Sci       Date:  2015-06-09       Impact factor: 5.923

8.  Characterization of invasive Neisseria meningitidis strains from Québec, Canada, during a period of increased serogroup B disease, 2009-2013: phenotyping and genotyping with special emphasis on the non-carbohydrate protein vaccine targets.

Authors:  Dennis K S Law; Brigitte Lefebvre; Rodica Gilca; Saul Deng; Jianwei Zhou; Philippe De Wals; Raymond S W Tsang
Journal:  BMC Microbiol       Date:  2015-07-25       Impact factor: 3.605

9.  Progressive decrease in the potential usefulness of meningococcal serogroup B vaccine (4CMenB, Bexsero®) in Gipuzkoa, Northern Spain.

Authors:  Emilio Pérez-Trallero; Olatz Esnal; José M Marimón
Journal:  PLoS One       Date:  2014-12-26       Impact factor: 3.240

Review 10.  Broad vaccine protection against Neisseria meningitidis using factor H binding protein.

Authors:  Jamie Findlow; Christopher D Bayliss; Peter T Beernink; Ray Borrow; Paul Liberator; Paul Balmer
Journal:  Vaccine       Date:  2020-08-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.